Clinical Trial

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-04-07; most recent amendment 2025-08-20.
Trial Details
NCT Number NCT05822908
Lead Sponsor Vico Therapeutics B. V.
Conditions Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Enrollment 68 participants
Start Date 2023-02-14
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-10-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-28